Red blood cell derived nanocarrier drug delivery system: A promising strategy for tumor therapy

Author:

Wang Xin123,Mao Kuirong124,Zhang Xiaonan5,Zhang Yuning124,Yang Yong‐Guang124,Sun Tianmeng1246ORCID

Affiliation:

1. Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education Institute of Immunology The First Hospital Jilin University Changchun Jilin China

2. National‐local Joint Engineering Laboratory of Animal Models for Human Diseases Changchun Jilin China

3. Medical Laboratory Center Affiliated Hospital of Inner Mongolia Minzu University Tongliao Inner Mongolia China

4. International Center of Future Science Jilin University Changchun Jilin China

5. Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden

6. State Key Laboratory of Supramolecular Structure and Materials Jilin University Changchun Jilin China

Abstract

AbstractNano drug delivery systems have been widely used in tumor therapy. Researchers have been devoted to exploring novel nano‐carriers to prolong circulation time biocompatibility and tumor targeting efficiency in vivo. Erythrocyte membranes as bionic nano‐drug delivery systems have attracted more attention recently. There are abundant red blood cells (RBCs) in circulation, which are natural carriers for nanomaterial delivery. There are mainly two strategies to use RBCs as nanomaterial carriers: RBC‐hitchhiking and bionic nanomaterial coated with erythrocyte membrane loading with drugs. Although nano‐carrier based on RBCs have yielded some progress, the mechanism of mutual effect between nanoparticles and RBCs is still unclear. Here, we review the effects of nanoparticles on RBCs (morphology and function, etc) and application of RBCs membrane as nano‐drug delivery carriers in tumor therapy.

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3